CLINICAL_TRIALS
trial_result
· 2011-07-08
Clinical Trial Update: Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer [Phase 2]
Summary
Phase 2 trial evaluating Vandetanib (ZD6474) for metastatic papillary or follicular thyroid cancer has completed with results posted in 2011.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Genzyme, a Sanofi Company | Conditions: Thyroid Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2011-07-08